Anti-DUSP9 antibody produced in rabbit

DUSP9 (dual specificity phosphatase 9) is predominantly expressed in the placenta and developing liver during early development and organogenesis. DUSP9 (dual specificity phosphatase 9) is predominantly expressed in the placenta and developing liver during early development and organogenesis.

Dual specificity protein phosphatase 9 recombinant protein epitope signature tag (PrEST)

All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive characterization in the industry.

The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. We also provide Prestige Antibodies^® protocols and other useful information.

DUSP9 (dual specificity phosphatase 9) gene encodes a cytoplasmic protein belonging to the dual specificity protein phosphatase subfamily. These proteins dephosphorylate both the phosphoserine/threonine and phosphotyrosine residues in the target kinases and deactivate them. Dusp9 preferentially recognizes and inactivates classical ERK1 (extracellular signal-regulated kinase-1) and -2 MAPKs (mitogen-activated protein kinases) in mammalian cells that are associated with cellular proliferation and differentiation. It protects against the development of insulin resistance by inactivating the mediators involved in stress-induced insulin resistance. It may serve as a therapeutic target for insulin-resistant disorders.

Prestige Antibodies^® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies^® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section.

Every Prestige Antibody is tested in the following ways:

• IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues.
• Protein array of 364 human recombinant protein fragments.

Solution in phosphate-buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide

Corresponding Antigen APREST74382

Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.